Advertisement

Evaluation Criteria in Comparative Clinical Trials in Advanced Breast Cancer: A Proposal for Improvement

  • K. W. Brunner
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Clinical trials in metastatic breast cancer and other presently incurable diseases may have three basically different aims:
  1. a)

    The development of new drugs or new modalities of treatment in Phase I and Phase II trials

     
  2. b)

    The development of new drug combinations or schedules which may eventually produce long-term survival and cure

     
  3. c)

    The selection of optimal treatments in terms of palliation (quality of life) and time (quantity of life).

     

Keywords

Breast Cancer Remission Rate Palliative Therapy Remission Duration Comparative Clinical Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mouridsen HT: Value and limitation of current criteria for assessing response. In: Cavalli F (ed) Endocrine Treatment of Breast Cancer II: Current Developments and New Methodologies. European School of Oncology Monograph Series, Springer Verlag, Berlin, Heidelberg, New York 1987Google Scholar
  2. 2.
    Henderson IC, Hayes DF, Come S, Harris JR, Canellos G: New agents and new medical treatments for advanced breast cancer. Sem in Oncol 1987 (14):34–64Google Scholar
  3. 3.
    Brunner KW: Problematik randomisierter Studien zur Definition optimaler Therapien beim metastasierenden Mammakarzinom. In: Nagel GA (ed) Mammakarzinome. Springer Verlag, Berlin, Heidelberg, New York 1986, pp 71–83Google Scholar
  4. 4.
    Carter SK: The role of clinical trials. In: Veronesi U and Bonadonni G (eds) Clinical Trials in Cancer Medicine. Academic Press 1986 pp 1–24Google Scholar
  5. 5.
    Gelber RD, Goldhirsch A for the Ludwig Breast Cancer Study Group: A new endpoint for the measurement of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986 (4):1772–1779PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • K. W. Brunner
    • 1
  1. 1.Institute of Medical OncologyInselspitalBernSwitzerland

Personalised recommendations